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Chemotherapy in gastric cancer: a never 
ending saga
For a long period of time, gastric carcinoma was considered to be
a poorly chemoresponsive tumor. Before the CT-scan era, clin-
ical investigations were not reliable by today’s standards because
of the paucity of good radiological tools, and because patients
without measurable disease were also enrolled. The so-called
‘first-generation’ drug combinations, designed before the
introduction of cisplatin to the treatment of this disease, gave
disappointing results [1–4]. The combination of mitomycin C,
doxorubicin and 5-fluorouracil (5-FU) (FAM) was considered a
standard for more than a decade.
In the late 1980s, attempts were made to increase the efficacy
of chemotherapy by designing more intensive regimens. The
combination of 5-FU–doxorubicin–methotrexate (FAMTX) with
high-dose methotrexate (MTX) and leucovorin (LCV) rescue
was designed in that spirit. This combination was shown, in a
randomized fashion, to be superior to FAM with a response rate
of 41% for FAMTX versus 9% for FAM, and a median survival
of 42 weeks versus 29 weeks, respectively [5–7]. FAMTX
became, therefore, the suggested European gold standard of
the early 1990s. Other investigators introduced cisplatin in the
treatment for gastric cancer. Cytotoxic regimens such as 5-FU–
cisplatin (FUP), 5-FU–leucovorin–cisplatin (FLP), cisplatin–
epirubicin–leucovorin–5-FU (PELF), etoposide–doxorubicin–
cisplatin (EAP) or even etoposide–5-FU–leucovorin (ELF) were
developed and originally shown to yield response rates (RRs)
ranging from 37% to 72%, with median response durations of
4–7 months, according to the non-randomized phase II studies
considered [8–13]. Unfortunately, results observed in subsequent
randomized trials comparing second-generation regimens with
each other, or with older treatment schemes were less convincing
[13–16]. These results diminished the original enthusiasm arising
from the excellent results of earlier phase II studies, and demon-
strated the fragility of results based on monocentric or oligo-
centric accruals [17]. These data also underscored the need for
new approaches and for new active agents.
In the 1990s, two new approaches were investigated. The first
consisted of increasing the efficacy by raising the dose intensity
of the chemotherapy [18, 19]. An intensive weekly chemotherapy
called EPFL, containing epirubicin, cisplatin, 5-FU and leuco-
vorin, was studied in Italy and reported a 62% response rate in a
large phase II trial of 105 patients [20]. However, toxicity was
substantial, requiring regular use of colony-stimulating factors.
The second approach, developed mainly at the Royal Marsden
Hospital, UK, was based on new schedules of administration of
5-FU, as proposed by Lokich et al. in the treatment of colorectal
cancer [18, 21]. A regimen of epirubicin, cisplatin and 5-FU
(ECF) in continuous infusion was developed in the UK. Impres-
sive RRs as high as 71% with 12% complete responses (CR) were
obtained in a phase II setting [22–24]. Compared with FAMTX,
in a phase III randomized study, ECF yielded a higher RR (45%
versus 21%, P = 0.0002), a superior median time to progression
(7.4 months versus 3.4 months) and an enhanced overall survival
(8.9 months versus 5.7 months, P = 0.0009). These data led the
investigators to propose ECF as standard practice [25].
Over the last 5 years, several new drugs have been successfully
tested against gastric cancer. Among them, we find the taxanes
[paclitaxel (Taxol®) and docetaxel (Taxotere®)], the topoisomer-
ase I inhibitor irinotecan, also called CPT-11 (Campto®), and,
more recently, the cisplatinum derivative oxaliplatin (Eloxatin®),
known for having a profile of activity different from its parent
compound. Other drugs such as oral 5-FU analogs and prodrugs,
including S-1 and capecitabine (Xeloda®), might also be attract-
ive for this indication in place of i.v. 5-FU [26–28]. Response
rates of up to 65% were obtained in phase II studies evaluating
taxane, irinotecan or oxaliplatin containing regimens [29–37].
They generated a large amount of enthusiasm despite median
overall survivals still in the 10 month range. Randomized phase
III trials intended to confirm these results are currently ongoing.
In this issue of Annals of Oncology, Kruijtzer et al. present
results of a phase II trial investigating the activity of oral pacli-
taxel in co-administration with cyclosporin A (CsA) as first-line
treatment in patients with advanced gastric cancer [38]. The co-
administration of CsA is aimed at blocking multidrug resistance
(MDR) activity, which could interfere with paclitaxel intra-
cellular efficacy, as well as at depressing the liver cytochrome
P450 system involved in paclitaxel metabolism. At the expense
of relatively little toxicity, they report an overall response rate of
32%, which is amazingly high for a single drug in this indication.
The CsA contribution to these results, by whatever pharmaco-
logical pathway, is difficult to assess. In that respect, we can
recall that pharmacological MDR modulation by CsA, verapamil
and other drugs has been investigated for more than a decade
without much clinically meaningful success so far [39–41].
Is the report by Kruijtzer et al. simply another phase II report to
take stock of in the metastatic gastric cancer saga? At first glance
we could say “yes”. However, even in the absence of data from
randomized trials, if we look carefully at the results obtained in
single-arm studies with new agents, we can extract some insight
of improvement. One of the interesting issues is that many of
these new agents have been shown to retain significant activity in
second-line therapy [42–45]. Likewise, patients failing first-line
treatment with these new drugs can still respond to another drug
combination [46]. These observations open the way to second-
line therapy for metastatic gastric cancer. As in breast cancer,
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where many metastatic patients can benefit from different lines of
treatment, some responding gastric cancer patients could now
benefit from additional lines of systemic therapy based on these
new agents. These new agents also offer us the possibility of pro-
viding patients with regimens better adapted to their condition.
Both taxanes and irinotecan can now be given on a weekly basis,
allowing a reduction in toxicity and the adaption of prescriptions
according to patient tolerance.
The report by Kruijtzer et al. brings another dimension to these
‘little’ improvements: the possibility to treat patients orally.
Efficacy and tolerance seem to compare favorably with equi-
valent i.v. schedules. As mentioned above, some patients with
metastatic gastric cancer will survive long enough to receive
several lines of therapy. The availability of an oral regimen
would be welcome and may enhance their quality of life. As
pointed out by the authors, oral paclitaxel could be combined
with capecitabine and provide a completely oral regimen. Oral
CPT-11 is also presently being tested in phase I trials and could
soon join the club of oral drugs available for gastric cancer.
It is unlikely that, even with positive randomized trial results,
these new active agents will bring a significant breakthrough in
the treatment of metastatic gastric cancer. They will, however,
provide us with additional tools for a better management of this
disease. Likewise, their integration into the multidisciplinary
approach for the cure of resectable disease may be worthwhile
and may need to be explored [47]. The never ending saga will go
on, but, it may be somehow, a worthwhile saga.
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